1. Home
  2. MFA vs ANNX Comparison

MFA vs ANNX Comparison

Compare MFA & ANNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo MFA Financial Inc.

MFA

MFA Financial Inc.

HOLD

Current Price

$9.52

Market Cap

1.0B

Sector

Real Estate

ML Signal

HOLD

Logo Annexon Inc.

ANNX

Annexon Inc.

HOLD

Current Price

$5.04

Market Cap

812.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MFA
ANNX
Founded
1997
2011
Country
United States
United States
Employees
N/A
93
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
812.7M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
MFA
ANNX
Price
$9.52
$5.04
Analyst Decision
Buy
Strong Buy
Analyst Count
6
6
Target Price
$11.05
$16.50
AVG Volume (30 Days)
1.4M
1.9M
Earning Date
05-05-2026
05-11-2026
Dividend Yield
14.16%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$10.02
$16,320.74
P/E Ratio
$7.75
N/A
Revenue Growth
N/A
N/A
52 Week Low
$8.78
$1.85
52 Week High
$10.57
$7.18

Technical Indicators

Market Signals
Indicator
MFA
ANNX
Relative Strength Index (RSI) 43.43 34.74
Support Level $9.38 $4.79
Resistance Level $9.79 $5.07
Average True Range (ATR) 0.21 0.28
MACD -0.05 -0.09
Stochastic Oscillator 19.20 16.39

Price Performance

Historical Comparison
MFA
ANNX

About MFA MFA Financial Inc.

MFA Financial Inc is a specialty finance company that invests in and finances residential mortgage assets. Its principal business objective is to deliver shareholder value through the generation of distributable income and through asset performance linked to residential mortgage credit fundamentals. The company selectively invests in residential mortgage assets with a focus on credit analysis, projected prepayment rates, interest rate sensitivity and expected return. The company's reportable segments include mortgage-related assets and Lima One.

About ANNX Annexon Inc.

Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502, for Oral small molecule; and ANX009, for systemic autoimmune diseases.

Share on Social Networks: